1. Pink Sheet

AbbVie’s Aquipta & GSK’s Jesduvroq Move Closer To EU Market

 
• By Neena Brizmohun

AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.

Close-up of European Names on Maps
Two new drugs are set to be approved for use in Europe soon • Source: Shutterstock

The European Medicines Agency has recommended that two new drugs be approved for marketing in the EU – AbbVie’s Aquipta (atogepant monohydrate), for the prophylaxis of migraine, and GSK’s Jesduvroq (daprodustat), for treating adults with anemia associated with chronic kidney disease (CKD).

On the other hand, the agency said that Amylyx Pharmaceuticals’ Albrioza should not be approved for treating amyotrophic lateral sclerosis in the EU. Amylyx is planning to appeal against the EMA’s decision on the drug, which is approved in the US and in Canada (with conditions)

More from Europe

More from Geography

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.